Xinmei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinmei Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Xiufeng Huang
Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
3 shared publicationsHong Xu
Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR China
2 shared publicationsJing Zhang
Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR China
2 shared publicationsLibo Zhu
The Department of Gynecology, Women's Hospital School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou, Zhejiang, 310006, People's Republic of China
2 shared publicationsPing Xu
Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
2 shared publicationsShaojie Ding
Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
2 shared publications
Latest Publications
- 1 July 2018
- Published by Springer Nature in Reproductive Sciences
- Vol. 25 (7) , 1045-1057
Role of Brain-Derived Neurotrophic Factor in Endometriosis Pain
Brain-derived neurotrophic factor (BDNF) is a regulator for the formation and maintenance of chronic pain in various chronic disorders and has been shown to increase in the serum of women with endometriosis. However, BDNF expression in the peritoneal fluid (PF) and ectopic lesions and its role in endometriosis pain remain unclear. Thus, this study aims to determine the BDNF concentrations in serum and PFs and BDNF expression levels in ectopic lesions and endometriotic stromal cells (ESCs) of women with endometriosis (n = 60). The obtained results were then compared with those of women without endometriosis (n = 38). Brain-derived neurotrophic factor concentrations in serum and PF, as well as the BDNF expression levels in ectopic lesions and endometriotic cells, were evaluated through enzyme-linked immunosorbent assay, immunohistochemical staining, quantitative real-time polymerase chain reaction, and Western blot analysis. As a result, BDNF concentrations in serum and PF were significantly higher in women with endometriosis with pain (2284.3 ± 51.5 pg/mL, n = 23; 58.8 ± 6.4 pg/mL, n = 16) than in women with endometriosis without pain (1999.8 ± 61.1 pg/mL, n = 37; 31.7 ± 2.9 pg/mL, n = 25; P < .01). Moreover, BDNF messenger RNA (mRNA) expression levels in ectopic lesions (8.97 ± 1.44, n = 29) were significantly higher than eutopic (0.97 ± 0.14, n = 16; P < .01) and control endometrium (1.23 ± 0.19, n = 18; P < .01) and were correlated with endometriosis pain (P < .05). Furthermore, increased BDNF mRNA and protein expression levels in ESCs induced by estradiol or interleukin 1β were removed using a phosphorylated extracellular-regulated protein kinase 1/2 inhibitor. These results suggest that BDNF may play an important role in the pathogenesis of endometriosis pain.
- 1 July 2018
- Published by Springer Nature in Reproductive Sciences
- Vol. 25 (7) , 1045-1057
Role of Brain-Derived Neurotrophic Factor in Endometriosis Pain
Brain-derived neurotrophic factor (BDNF) is a regulator for the formation and maintenance of chronic pain in various chronic disorders and has been shown to increase in the serum of women with endometriosis. However, BDNF expression in the peritoneal fluid (PF) and ectopic lesions and its role in endometriosis pain remain unclear. Thus, this study aims to determine the BDNF concentrations in serum and PFs and BDNF expression levels in ectopic lesions and endometriotic stromal cells (ESCs) of women with endometriosis (n = 60). The obtained results were then compared with those of women without endometriosis (n = 38). Brain-derived neurotrophic factor concentrations in serum and PF, as well as the BDNF expression levels in ectopic lesions and endometriotic cells, were evaluated through enzyme-linked immunosorbent assay, immunohistochemical staining, quantitative real-time polymerase chain reaction, and Western blot analysis. As a result, BDNF concentrations in serum and PF were significantly higher in women with endometriosis with pain (2284.3 ± 51.5 pg/mL, n = 23; 58.8 ± 6.4 pg/mL, n = 16) than in women with endometriosis without pain (1999.8 ± 61.1 pg/mL, n = 37; 31.7 ± 2.9 pg/mL, n = 25; P < .01). Moreover, BDNF messenger RNA (mRNA) expression levels in ectopic lesions (8.97 ± 1.44, n = 29) were significantly higher than eutopic (0.97 ± 0.14, n = 16; P < .01) and control endometrium (1.23 ± 0.19, n = 18; P < .01) and were correlated with endometriosis pain (P < .05). Furthermore, increased BDNF mRNA and protein expression levels in ESCs induced by estradiol or interleukin 1β were removed using a phosphorylated extracellular-regulated protein kinase 1/2 inhibitor. These results suggest that BDNF may play an important role in the pathogenesis of endometriosis pain.
- 26 November 2016
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 295 (3) , 631-639
Elevated RON protein expression in endometriosis and disease-associated ovarian cancers
Background Recepteur d’origine nantais (RON) protein expression has been demonstrated to correlate with tumor progression, metastasis, and prognosis, and its mRNA expression increases in deeply infiltrating endometriotic lesions. However, it remains unclear whether RON protein expression also increases in endometriotic lesions, and may be a risk factor of malignant transformation in endometriotic lesions. Methods The protein expression of RON in control (n = 19), eutopic (n = 16), and ectopic (n = 51) endometria, as well as in endometriosis-associated ovarian cancers (EAOC, n = 16) was determined by immunohistochemical (IHC) staining. Results Endometriotic lesions expressed low levels of RON protein, but no RON protein expression appeared in matched eutopic or control endometrium. EAOC exhibited high levels of RON protein. The frequency and IHC score of RON protein expression were both significantly higher in EAOC [100.0% (14/14), 5.37 ± 0.74] than those in endometriotic lesions [51.0% (26/51), 2.15 ± 1.12; P = 0.002, 0.001]. Multivariate analysis of covariance only revealed a correlation of RON protein expression and EAOC (P = 0.006), but no correlations of RON protein expression and clinical parameters (P > 0.05). Conclusions These obtained results suggest that increased RON expression might be involved in the pathogenesis of endometriosis and disease-associated ovarian cancers.
- 26 November 2016
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 295 (3) , 631-639
Elevated RON protein expression in endometriosis and disease-associated ovarian cancers
Background Recepteur d’origine nantais (RON) protein expression has been demonstrated to correlate with tumor progression, metastasis, and prognosis, and its mRNA expression increases in deeply infiltrating endometriotic lesions. However, it remains unclear whether RON protein expression also increases in endometriotic lesions, and may be a risk factor of malignant transformation in endometriotic lesions. Methods The protein expression of RON in control (n = 19), eutopic (n = 16), and ectopic (n = 51) endometria, as well as in endometriosis-associated ovarian cancers (EAOC, n = 16) was determined by immunohistochemical (IHC) staining. Results Endometriotic lesions expressed low levels of RON protein, but no RON protein expression appeared in matched eutopic or control endometrium. EAOC exhibited high levels of RON protein. The frequency and IHC score of RON protein expression were both significantly higher in EAOC [100.0% (14/14), 5.37 ± 0.74] than those in endometriotic lesions [51.0% (26/51), 2.15 ± 1.12; P = 0.002, 0.001]. Multivariate analysis of covariance only revealed a correlation of RON protein expression and EAOC (P = 0.006), but no correlations of RON protein expression and clinical parameters (P > 0.05). Conclusions These obtained results suggest that increased RON expression might be involved in the pathogenesis of endometriosis and disease-associated ovarian cancers.
- 25 May 2016
- Vol. 45 (4) , 439-445
上皮间充质转化介导子宫内膜异位症发生发展的研究进展
上皮间充质转化在子宫内膜异位症的发生和发展中扮演重要角色,间充质上皮转化参与内异症局部病灶的形成,上皮间充质转化参与内异症局部炎症损伤、修复和纤维化与细胞侵袭和转移的过程。通过研究上皮间充质转化在内异症进程中特征性的信号传导通路及分子蛋白,可以为发现内异症新的诊断和治疗方案提供思路。
- 25 May 2016
- Vol. 45 (4) , 439-445
上皮间充质转化介导子宫内膜异位症发生发展的研究进展
上皮间充质转化在子宫内膜异位症的发生和发展中扮演重要角色,间充质上皮转化参与内异症局部病灶的形成,上皮间充质转化参与内异症局部炎症损伤、修复和纤维化与细胞侵袭和转移的过程。通过研究上皮间充质转化在内异症进程中特征性的信号传导通路及分子蛋白,可以为发现内异症新的诊断和治疗方案提供思路。
- Open Access
- 13 March 2015
- Published by Springer Nature in BMC Women's Health
- Vol. 15 (1) , 24
Efficacy of laparoscopic adenomyomectomy using double-flap method for diffuse uterine adenomyosis
Adenomyomectomy has recently been considered the priority option for the treatment of adenomyosis, however, the surgical efficacy and modes are still debated. We aimed to evaluate the efficacy of laparoscopic adenomyomectomy using a double-flap method for the treatment of uterine diffuse adenomyosis when compared with conventional laparoscopic adenomyomectomy. Laparoscopic adenomyomectomy using the conventional method (group A, n = 48) and the double-flap method (group B, n = 46) to treat diffuse uterine adenomyosis, respectively. Visual analog scale (VAS), menstrual amount, serum CA125 levels, and uterine volume were comparatively analyzed in both groups. The VAS scores, menstrual amount, serum CA125 levels, and uterine volume at 12 or 24 months after surgery significantly reduced in group B than in group A (P < 0.05); these parameters were statistically decreased in both groups after surgery compared with those obtained before surgery (P < 0.001). Moreover, serum CA125 levels and uterine volume at six months of follow up were significantly lower in group B than in group A (P < 0.01). In addition, blood loss during surgery was similar in groups A and B (P > 0.05), although the operative time was significantly longer in group B than that in group A (P < 0.05). Laparoscopic adenomyomectomy using the double-flap method may be an effective technique to treat uterine diffuse adenomyosis.
- 13 March 2015
- Published by Springer Nature in BMC Women's Health
- Vol. 15 (1) , 24
Open AccessEfficacy of laparoscopic adenomyomectomy using double-flap method for diffuse uterine adenomyosis
Adenomyomectomy has recently been considered the priority option for the treatment of adenomyosis, however, the surgical efficacy and modes are still debated. We aimed to evaluate the efficacy of laparoscopic adenomyomectomy using a double-flap method for the treatment of uterine diffuse adenomyosis when compared with conventional laparoscopic adenomyomectomy. Laparoscopic adenomyomectomy using the conventional method (group A, n = 48) and the double-flap method (group B, n = 46) to treat diffuse uterine adenomyosis, respectively. Visual analog scale (VAS), menstrual amount, serum CA125 levels, and uterine volume were comparatively analyzed in both groups. The VAS scores, menstrual amount, serum CA125 levels, and uterine volume at 12 or 24 months after surgery significantly reduced in group B than in group A (P < 0.05); these parameters were statistically decreased in both groups after surgery compared with those obtained before surgery (P < 0.001). Moreover, serum CA125 levels and uterine volume at six months of follow up were significantly lower in group B than in group A (P < 0.01). In addition, blood loss during surgery was similar in groups A and B (P > 0.05), although the operative time was significantly longer in group B than that in group A (P < 0.05). Laparoscopic adenomyomectomy using the double-flap method may be an effective technique to treat uterine diffuse adenomyosis.
- 1 June 2014
- Published by Elsevier in Acta Histochemica
- Vol. 116 (5) , 871-877
Decreased nerve fibers in the oviduct isthmus of women with endometriosis
- 1 June 2014
- Published by Elsevier in Acta Histochemica
- Vol. 116 (5) , 871-877
Decreased nerve fibers in the oviduct isthmus of women with endometriosis
- 1 April 2014
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 175, 87-91
Is nerve-sparing surgery suitable for deeply infiltrating endometriosis?
- 1 April 2014
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 175, 87-91
Is nerve-sparing surgery suitable for deeply infiltrating endometriosis?